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Abstract
Sodium glucose transporters (SGLTs) belong to the mammalian solute carrier family SLC5. This family includes 12 different
members in human that mediate the transport of sugars, vitamins, amino acids, or smaller organic ions such as choline. The SLC5
family belongs to the sodium symporter family (SSS), which encompasses transporters from all kingdoms of life. It furthermore
shares similarity to the structural fold of the APC (amino acid-polyamine-organocation) transporter family. Three decades after
the first molecular identification of the intestinal Na+-glucose cotransporter SGLT1 by expression cloning, many new discoveries
have evolved, from mechanistic analysis to molecular genetics, structural biology, drug discovery, and clinical applications. All
of these advances have greatly influenced physiology and medicine. While SGLT1 is essential for fast absorption of glucose and
galactose in the intestine, the expression of SGLT2 is largely confined to the early part of the kidney proximal tubules, where it
reabsorbs the bulk part of filtered glucose. SGLT2 has been successfully exploited by the pharmaceutical industry to develop
effective new drugs for the treatment of diabetic patients. These SGLT2 inhibitors, termed gliflozins, also exhibit favorable
nephroprotective effects and likely also cardioprotective effects. In addition, given the recent finding that SGLT2 is also
expressed in tumors of pancreas and prostate and in glioblastoma, this opens the door to potential new therapeutic strategies
for cancer treatment by specifically targeting SGLT2. Likewise, further discoveries related to the functional association of other
SGLTs of the SLC5 family to human pathologies will open the door to potential new therapeutic strategies. We furthermore hope
that the herein summarized information about the physiological roles of SGLTs and the therapeutic benefits of the gliflozins will
be useful for our readers to better understand the molecular basis of the beneficial effects of these inhibitors, also in the context of
the tubuloglomerular feedback (TGF), and the renin-angiotensin system (RAS). The detailed mechanisms underlying the clinical
benefits of SGLT2 inhibition by gliflozins still warrant further investigation that may serve as a basis for future drug
development.
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Expression cloning to unveil the molecular
structure and function of sodium glucose
cotransporters
The concept that transport of glucose across the intestinal
brush border membrane (BBM) requires an active mechanism
that is achieved through coupling of transport to the inwardly
directed Na+ gradient has already been disclosed in 1960 [26].
It was subsequently refined and extended to cover active
transport of a variety of molecules, including nutrients, neu-
rotransmitters, metabolites, and electrolytes. These trans-
porters are called cotransporters or symporters and they
This article is part of the special issue on Glucose Transporters in Health
and Disease in Pflügers Archiv—European Journal of Physiology
* Matthias A. Hediger
matthias.hediger@ibmm.unibe.ch; https://www.bioparadigms.org
1 Membrane Transport Discovery Lab, Department of Nephrology and
Hypertension, and Department of Biomedical Research, Inselspital,
University of Bern, Kinderklinik, Office D845, Freiburgstrasse 15,
CH-3010 Bern, Switzerland
2 Department of Bio-system Pharmacology, Graduate School of
Medicine, Osaka University, Osaka, Japan
https://doi.org/10.1007/s00424-020-02433-x
/ Published online: 7 August 2020
Pflügers Archiv - European Journal of Physiology (2020) 472:1177–1206
usually link uphill solute transport to the cotransport of Na+ or
H+ [70]. The primary sequences of the corresponding trans-
porters, however, remained unknown until later in 1980, when
expression cloning approach was discovered, because the hy-
drophobic nature of these integral membrane proteins preclud-
ed their isolation in a form suitable for amino acid sequencing.
The needed approach was conceptualized based on the obser-
vations that micro-injection of mRNA from rabbit small intes-
tine into Xenopus laevis oocytes (X. oocytes) stimulated Na+-
dependent and phlorizin-sensitive uptake of 14C-α-methyl-D-
glucopyranoside (14C-α-MG), the specific substrate of the
intestinal sodium-glucose cotransporter and that micro-
injection of size-fractionated intestinal poly(A) RNA of about
2.4 kb specifically induced this transport function [68]. The X.
oocyte expression system offered a convenient method for this
purpose, as the relatively large cells (~ 0.8–1.3 mm diameter)
easily allowed the micro-injection of poly(A) RNA (or cRNA
derived from cDNA clones), and 3 days after injection, the
encoded transporters could already be detected in the oocyte
cell membrane using radio-isotope uptake studies or two-
electrode voltage clamping (TEVC). A cDNA transcription
library was then generated from the active size fraction,
cDNA clones were screened functionally for their ability to
induce uptake of 14C-α-MG, and a positive clone was identi-
fied, sequenced, and fully characterized in terms of its struc-
ture, function, and physiological roles [67]. Soon thereafter,
the approach resulted in the identification of the primary struc-
ture of the human intestinal Na+/glucose cotransporter SGLT1
(SLC5A1) [67]. During the following years, expression clon-
ing became the premier method to isolate transporter clones,
as it did not require any DNA or antibody probes to screen
cDNA libraries, only transporter-specific functional assays
[141]. Indeed, this approach has revealed the structural and
mechanistic foundations for transporters of iron (SLC11A2/
DMT1/DCT1) [61], vitamin C (SLC23A1/SVCT1 and
SLC23A2/SVCT2) [124], urea (SLC14A2/UT1) [206], gluta-
mate (SLC1A1/EAAC1) [75], dibasic amino acids (SLC3A1/
D2) [197], oligopeptides (SLC15A1/PepT1) [42], myoinosi-
tol (SLC5A3/SMIT) [90], iodide (SLC5A5/NIS) [27], and the
epithelial calcium channel TRPV6/CaT1 [124]. The human
homolog of rabbit SGLT1 (SLC5A1) [69] and the kidney-
specific human homolog SGLT2 (SLC5A2) [76, 198] were
subsequently identified. Using expression cloning with co-
expression of SGLT2, an important activator, named
MAP17, of SGLT2 was furthermore identified by expression
cloning [23]. Overall, it soon became apparent that the sodium
glucose cotransporters (SGLTs) belonged to a larger family of
transporters, including members in lower organisms such as
the Escherichia coli Na+/proline cotransporter PutP. Three
decades after the initial cloning of the rabbit intestinal Na+-
glucose cotransporter SGLT1, many new discoveries have
beenmade in the field, frommechanistic analysis to molecular
genetics, structural biology, drug discovery, and clinical
applications. All of these advances have greatly shaped phys-
iology and medicine [202].
Brief description of key properties, expression
patterns, physiological and pathological
implications of SLC5 family members
The human SLC5 solute carrier family includes 12 members.
It is part of the sodium symporter family (SSS) that encom-
passes members from all kingdoms of life. The SSS family is
also annotated in TCDB [147] as family #2.A.21, and the
corresponding transmembrane domain in Pfam database [37]
as “SSF” (“sodium:solute symporter family,” Pfam ID:
PF00474). SLC5 members typically transport small solutes,
such as sugars, vitamins, amino acids, or smaller organic ions
such as choline or monocarboxylates (short chain fatty acids).
Proposed evolutionary relationships between human SLC5
members are shown in Fig. 1. Sequences of the 12 human
SLC5 members were downloaded from the UniProt database
[181], and aligned byClustal Omega [159, 160]. Based on this
multiple alignment, a phylogenetic tree was generated using
PhyML 3.0 with smart model selection (SMS) [60, 94] with
default settings (Fig. 1). The resulting tree shows a
Fig. 1 Phylogenetic tree of human SLC5 members. The physiological
substrates of individual transporters are indicated (SCFA: short chain
fatty acids). The phylogenetic tree was visualized with the Interactive
Tree of Life (iTOL) server [95]
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partitioning of human SLC5 proteins in accordance with sub-
strate selectivity, whereby the sugar transporters appear to be
more closely related to each other than to non-sugar trans-
porters. Human SLC5A7, which is a Na+/Cl−-coupled choline
transporter, seems to be more distantly related to other SLC5
members.
SLC5A1/SGLT1
SGLT1 was the first member of the SLC5 family to be cloned
[67, 69] and it has been extensively studied during the past
4 decades [66, 71, 200, 202]. Its main function is the absorp-
tion of glucose and galactose across the intestinal brush-
border membrane. However, as outlined later on in this re-
view, it also plays a role in the reabsorption of these sugars
in the kidney, where it can be found in the regions S2 and S3
of the proximal tubules [64]. Mutations in this gene lead to the
intestinal glucose/galactose malabsorption (GGM, OMIM
#606824), a rare metabolic disorder that causes a severe diar-
rhea that can be fatal unless glucose and galactose are re-
moved from the diet [19, 201]. Moreover, as reflected by its
renal function, GGM patients present mild renal glucosuria
(see below), urinary tract infections, and calculus formation
[19, 200]. Due to the pivotal role of SGLT1 in glucose ab-
sorption in the intestine, which is accompanied by water ab-
sorption, a treatment promoting the activity of SGLT1, named
as oral rehydration therapy (ORT), is one of the standard med-
ical procedures to prevent and overcome secretory diarrhea-
related complications [71]. Recently, SGLT1 has been pro-
posed to contribute to a new variety of physiological process-
es, including glucose sensing in the brain [202], protection
against pathogens in activated lymphocytes [10], or embryon-
ic implantation [151].
SGLT1 transports the natural sugars glucose and galactose,
but not fructose or mannose. It is also able to transport some
non-metabolized glucose analogues, such as α-MG and 3-O-
methyl-glucose, but not 2-deoxy-glucose [71]. Regarding the
transport mechanism, sugar transport requires the cotransport
of Na+, which occurs with a stoichiometry of 2 Na+ ions per
each transported sugar molecule [21, 92]. In addition, it has
been proposed that SGLT1 can work as Na+ uniporter, and
even as a water and urea channel [71].
SLC5A2/SGLT2
SGLT2 is located in the apical membrane of the early renal
proximal convoluted tubule S1 segments [207], where it me-
diates the absorption of most of the glucose present in the
glomerular filtrate [76, 184, 198]. Mutations in the gene
encoding SGLT2 are responsible for familial renal glucosuria
(FRG, OMIM #233100) [109, 174], a disorder that results in
loss of glucose in the urine despite normal blood glucose
levels [19]. In fact, due to its highly specialized role in
proximal tubule glucose reabsorption, SGLT2 has been large-
ly studied by the pharmaceutical industry as a therapeutic
target to control glucose levels in diabetic patients [155,
170], as will be explained later on in detail. Moreover,
SGLT2-targeting drugs have received increasing attention
due to their cardioprotective effects in diabetic patients and,
thus, possible additional use as pharmaceutical tools to pre-
vent heart failure [187]. While the expression of SGLT2 is
mainly restricted to the early proximal tubules of the kidney,
interestingly, its expression has been detected in pancreas,
prostate tumors, and glioblastoma, which opens the door to
potential new strategies for cancer treatment by targeting
SGLT2 in those tissues [202].
Numerous in vivo experiments in the 1980s highlighted
the existence of a low-affinity glucose transport system in
the early proximal tubules [7]. Subsequently, SGLT2 was
successfully cloned and characterized in the early 1990s
[76, 198]. However, due to the low signal-to-noise ratio
observed for protein activity in the different expression
systems tested [71, 76, 207], an accurate and comprehen-
sive description of its transport mechanism remained elu-
sive for more than 2 decades. Nevertheless, recent studies
revealed that co-expression of SGLT2 with MAP17, a
small protein that interacts with SGLT2, greatly intensifies
its transport function [23]. This finding allowed to confirm
previous observations [71] that SGLT2 is a low-affinity
high-capacity transporter, very selective for glucose,
inhibited by phlorizin and that the Na+ to glucose cou-
pling stoichiometry is 1:1 [23]. Therefore, mechanistic de-
tails of SGLT2 transport function is expected to follow
soon, which will improve our molecular understanding of
its physiological and pharmacological properties.
SLC5A4/SGLT3 (also known as SAAT1)
Expression of human SGLT3 has been described in enteric
neurons of the intestinal epithelia and in neuromuscular
junctions of the skeletal muscle [35]. Interestingly, when
expressed in X. oocytes, this protein has shown to be
unable to transport glucose, while the binding still induces
currents through SGLT3-mediated depolarization of the
plasma membrane resting potential. SGLT3 binds glucose
with low affinity (Km = 20 mM), while galactose, fructose,
and mannitol do not interact with the protein. The
substrate-induced currents through SGLT3 are Na+-depen-
dent, increase in the presence of H+, and are specifically
inhibited by phlorizin [35]. Imino sugars were described
as potent and specific activators of the electrogenic prop-
erties of SGLT3. Interestingly, imino sugars are also used
to treat type 2 diabetes and lysosomal storage diseases
based on their inhibition of α-glucosidases and
glucosyltransferases [211]. Imino sugars may serve as tool
compounds to explore the precise physiological role of
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SGLT3 [190]. Due to its location in the enteric neurons
and its particular transport mechanism, it has been pro-
posed that SGLT3 works as a glucose sensor, the activity
of which might regulate the intestinal motility in response to
glucose [35]. Likewise, it was speculated that it could regulate
skeletal muscle activity by depolarizing neuromuscular junction
cells in response to glucose [35]. Recent studies provided evi-
dence for expression of SGLT3 in human kidney, where it might
contribute to Na+ transport in proximal tubules [88]. Also,
whole-exome sequencing identified a genetic variant of
SGLT3, which disrupts glucose-induced sodium conductance,
and is present in some patients affected by attention deficit/
hyperactivity disorder (ADHD). The co-segregation of the
SGLT3 variant and ADHD phenotype was, however, imperfect
[154]. Taken together, while the functional properties of SGLT3
have been studied by several investigators, its physiological role
is still the subject of debate [165]. The glucose-sensing mecha-
nism that has been proposed based on in vitro studies, showing
that SGLT3 generates membrane currents in the presence of high
concentrations of glucose, is lacking in vivo validation. Also, the
tissue localization of this protein needs to be clarified to help
predict its physiological role. In addition, the role of imino sugars
should be further investigated. The lack of a human disease
phenotype linked to the transporter malfunction and the absence
of appropriate transgenic animal models and inhibitors further
slowed down defining its true physiological role.
SLC5A9/SGLT4
The expression of SGLT4 in humans has been detected in the
small intestine and kidney [171]. Functional studies using
COS-7 cells overexpressing SGLT4 revealed that it is a Na+-
dependent α-MG transporter (Km = 2.6 mM). Moreover,
transport of α-MG was inhibited by mannose and glucose,
and to a lower extent by fructose and the metabolite 1,5-
anhydro-D-glucitol (1,5-AG). Direct measurements of man-
nose uptake by SGLT4 and the capacity of mannose to inhibit
SGLT4-mediated α-MG transport (IC50 = 0.15 mM) indicat-
ed that SGLT4 is a Na+-coupled mannose transporter [171].
Three rare variants of this gene were identified in patients of
proliferative diabetic retinopathy and it was suggested that this
protein is expressed in retinal endothelial cells, where it may
play a role in the pathogenesis of this disease [180]. Recent
genetic studies revealed that SGLT4 is expressed in kidney-
pancreatic-colorectal tumors, while not expressed in the
matched normal tissues [49]. Similarly, a genome-wide asso-
ciation study identified a SNP near the SGLT4 locus that
affects susceptibility for colorectal cancer development [44].
Overall, the lack of detailed functional information, together
with limited information regarding its expression profile, re-
sults in a poorly understood physiological role of this
transporter.
SLC5A10/SGLT5
SGLT5 has been shown to be highly expressed in human
kidney [58]. Immunolocalization revealed apical expression
in the proximal straight tubules [54]. Functional studies using
SGLT5-overexpressing TREX HEK293 cells revealed that it
is a mannose (Km = 0.45 mM) and fructose (Km = 0.62 mM)
transporter, which shows the typical functional character-
istics of the SLC5 glucose transporter family members,
such as the inhibition by phlorizin and Na+-dependence
of the transport process [58]. Due to its selectivity toward
fructose and mannose, it has been speculated that it is
responsible for reabsorption of these sugars from the glo-
merular filtrate. In support of this idea, studies of Slc5a10
knockout mice showed an increased loss of fructose in the
urine, without affecting the plasma levels of fructose [46].
Furthermore, studies of the renal reabsorption of fructose
in rat proximal tubules revealed that this process can be
blocked to a large extent by phlorizin and that it is Na+-
dependent [54]. In addition, recent genome-wide associa-
tion studies revealed that genetic variations of SGLT5 are
associated with impaired 1,5-anhydroglucitol (1,5-AG)
blood levels [96]. 1,5-AG is a monosaccharide found in
nearly all foods and its blood concentration decreases dur-
ing times of hyperglycemia and, within a couple of
weeks, returns to normal levels in the absence of hyper-
glycemia. Rare loss-of-function mutations of SGLT5 have
been associated with lower levels of 1,5-AG, indicating
that SGLT5 reabsorbs this monosaccharide [100]. In
healthy individuals, 1,5-AG level is kept relatively con-
stant through intestinal absorption and renal reabsorption.
Interestingly, 1,5-AG reabsorbed by the kidney is
inhibited by competition with glucose [203]. Thus, during
hyperglycemia, when the kidney cannot reabsorb all glu-
cose via SGLT1 and SGLT2, this leads to inhibition of
1,5-AG reabsorption, presumably via SGLT5, and there-
fore a decrease in the of 1,5-AG levels in the blood. Once
the hyperglycemia is corrected, 1,5-AG begins to be
reabsorbed from the kidney back into the blood at a
steady rate and if a person’s glucose levels remain below
10 mM for approximately 4 weeks, 1,5-AG will return to
its normal levels. The 1,5-AG test is currently FDA-
approved for diabetes patients to measure 1,5-AG levels
in the blood, in order to determine the history of hyper-
glycemic episodes [203], complementary to HbA1c and
fructosamine tests. Despite all these interesting recent
findings, only limited information is available about the
role of the SGLT5 transporter in health and disease and to
what extent its functional activity affects the 1,5-AG dia-
betes test. SGLT2 inhibitors, which lower blood glucose
and produce glycosuria, may likely cause abnormal circu-
lating 1,5-AG levels and, thus, could interfere with the
diabetes test.
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Other SLC5 family members
The SLC5 family comprises 12 members, including the
abovedescribed sugar transporters (SGLT1-5), in addition to
transporter for other substrates, such as the myo-inositol
(SLC5A3 and SLC5A11), iodide (SLC5A5), monocarboxyl-
ate (SLC5A8 and SLC5A12), choline (SLC5A7), and vitamin
(SLC5A6) transporters. All these membrane proteins share a
common transport mechanism, which uses the Na+ electro-
chemical gradient to sense (SGLT3) or incorporate their sub-
strates into cells.
SLC5A3/SMIT1 and SLC5A11/SMIT2
The SLC5A3Na+/myo-inositol transporter, known as SMIT1,
was found to be widely expressed in humans [9], with prom-
inent expression in the intestine and brain [5]. In addition to
myo-inositol (K0.5 = 50 μM), SMIT1 also transports D-glu-
cose with low affinity [200]. Studies with SMIT1 knockout
mice revealed that it plays an essential role in osteogenesis,
bone formation, and maintenance of bone mineral density
[28]. SMIT2 was identified as a major gene responsible for
the syndrome of infantile convulsions and paroxysmal dyski-
nesia (ICCA syndrome), as well as for benign familial infan-
tile convulsions (BFIC) [140]. As observed for SMIT1,
SMIT2 is expressed in a wide variety of human tissues
[140], but in contrast to SMIT1, SMIT2 does not transport
glucose [97]. Genetic studies have shown that SMIT2 inter-
acts with immune-related genes and it seems to be involved in
certain immune effects. Accordingly, it was proposed that
SMIT2 could function as an autoimmune modifier [176].
Recent studies revealed a strong correlation between the ex-
pression of the myo-inositol transporters SMIT1 and SMIT2
and psychiatric diseases, e.g. schizophrenia and bipolar disor-
der, and it was suggested that alterations in their expression in
specific brain regions account for the symptoms of these dis-
eases [188]. Another recent study showed an altered expres-
sion pattern of SMIT1 and SMIT2 in the sciatic nerve and
dorsal root ganglia in an experimental diabetes model, which
may play a role in the pathogenesis of diabetic neuropathy
[41].
SLC5A5/NIS
The Na+/iodide transporter SLC5A5, also known as NIS, is
highly expressed in the thyroid gland, where it mediates ac-
cumulation of iodide (I−), which is required for the biosynthe-
sis of the thyroid hormones T3 and T4 [30]. NIS is also
expressed in non-thyroid tissues, such as salivary glands,
stomach, lactating breast, and primary and metastatic breast
cancer [136]. In addition, NIS is expressed in the small intes-
tine, where it contributes to the absorption of dietary I− [114].
In addition to I−, NIS also transports thiocyanate (SCN−) and
chlorate (ClO3
−) with a stoichiometry of 2 Na+:1 substrate.
Interestingly, it also transports the pollutant perchlorate
(ClO4
−), although with a stoichiometry of 1:1 [123].
Mutations in the SLC5A5 gene lead to a condition known as
I− transport defect (ITD), which reduces the accumulation of
I− in the thyroid and results in hypothyroidism [136]. Due to
its pivotal role in I− absorption, NIS is the major target for
diagnosis and therapy of thyroid cancer using iodide radioiso-
topes, whereby its expression level is crucial for tumor prog-
nosis. The relatively high expression of NIS in breast cancer
also makes it a potential target for the treatment of the disease
[214].
SLC5A8/SMCT1 and SLC5A12/SMCT2
SMCT1 is a high-affinity membrane transporter of lactate, and
can also mediate the uptake of other monocarboxylates such
as pyruvate, butyrate, propionate, and acetate [105]. SMCT1
expression can be found in the intestinal colon and the kid-
neys, and to a lower extent, in the brain and retina [48]. In the
colon, SMCT1 is postulated to be responsible for the apical
uptake of short-chain fatty acids (SCFA) such as acetate, pro-
pionate, and butyrate generated by bacterial fermentation of
dietary fiber [11, 162]. SMCT2 is a low-affinity membrane
t r an spo r t e r o f l ac t a t e , a l so t r anspo r t i ng o the r
monocarboxylates, including pyruvate and nicotinate [55].
SMCT1 and SMCT2 are both Na+-coupled. SMCT1-mediat-
ed transport is electrogenic with a Na+ to SCFA stoichi-
ometry of 2:1, whereas SMCT2-mediated transport is
electroneutral (Na+ to SCFA stoichiometry of 1:1) [162].
Moreover, SMCT1 has been shown to function as a tumor
suppressor gene for colon, thyroid, stomach, kidney, and
brain tumors [48]. SMCT1 and SMCT2 are both
expressed in the apical membranes of the intestine and
kidneys. However, while SMCT1 is found mainly in co-
lon and outer kidney cortex, SMCT2 is present in the
proximal parts of the intestinal tract and both kidney cor-
tex and medulla [166]. Kidney-specific ablation of the
expression of SMCT1 and SMCT2 resulted in a marked
increase in urinary loss of lactate and a decrease in blood
levels, indicating that these transporters might be respon-
sible for renal lactate reabsorption [172]. A recent study
of protein-protein interactions revealed that the PDZK1
adaptor protein is a binding partner of both SMCT1 and
SMCT2 and additionally identified a molecular complex
of SMCT1-PDZK1 and the urate transporter URAT1
(SLC22A12) (see “transporter complex” in Fig. 4a on
the right). This suggests a possible role of SMCT1 in
urate reabsorption in the kidney [167]. Another quite re-
cent work showed the expression of both SMCT1 and
SMCT2 in pancreas and also that SMCT1 function can
be regulated by insulin [101].
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SLC5A7/CHT1
CHT1 is a high-affinity Na+/choline transporter (Km = 2 μM),
which is exclusively expressed in tissues containing choliner-
gic neurons. There, its transport activity constitutes the rate-
limiting step for acetylcholine synthesis [84, 118]. In contrast
to the other members of the SLC5 family, the transport pro-
cess mediated by CHT1 is Cl−-dependent and regulated by
extracellular pH [72]. CHT1 resides in intracellular compart-
ments and is translocated to the plasma membrane in response
to neuronal activity [62]. CHT1 knockout mice have a normal
embryonic development, but die after birth due to defective
cholinergic neurotransmission [43]. Patients with truncating
SLC5A7 mutations underlie a spectrum of dominant heredi-
tary motor neuropathies [152]. A single nucleotide polymor-
phism in the SLC5A7 gene with high prevalence in the Asian
population, resulting in a replacement of isoleucine by valine
in the third transmembrane domain, has been reported to de-
crease the ability of CHT1 to transport choline by about 50%,
thereby representing a risk factor for cholinergic dysfunction
in this population [62].
SLC5A6/SMVT
SMVT is a Na+-dependent transporter of the water-soluble
vitamins pantothenic acid, biotin, and α-lipoic acid, the latter
being a cofactor of several enzymes such as pyruvate dehy-
drogenase. Transport through SMVT is electrogenic and oc-
curs with a stoichiometry of 2 Na+ to 1 vitamin molecule
[177]. Like NIS (SLC5A5), to which it shows a high degree
of sequence identity, SMVT transports I− as well [29]. SMVT
is ubiquitously distributed in the human body. However,
stronger expression levels are found in absorptive tissues such
as the intestine, the kidney, and the placenta [132].
Studies of intestine-specific Slc5a6 knockout mice indi-
cated that SMVT is indispensable for intestinal biotin up-
take [52]. In addition, SMVT was found to be required to
keep a normal mucosal integrity [145]. Furthermore, it
was shown that the defects due to the absence of SMVT
in knockout mouse intestine can be reverted by biotin and
pantothenic acid supplementation [146]. A recent study
described a neurodegenerative disorder as consequence
of a biallelic mutation in the SLC5A6 gene, which could
be clinically improved by “triple vitamin” (biotin, panto-
thenate, and lipoate) replacement therapy [17]. Due to its
broad tissue distribution and substrate range, SMVT is
exploited as a drug delivery transport system to increase
the bioavailability of prodrugs as conjugates of biological
substrates of SMVT with drugs. For example, a biotinyl-
ated lipid prodrug of acyclovir has been generated for
improved cellular uptake via SMVT in corneal epithelial
cells, to be used for the treatment of herpes simplex virus
keratitis [182].
Description of the transport properties
of SGLT1 to SGLT5
The sodium-dependent glucose transporters or SGLTs are sec-
ondary active transporters present in the plasma membranes of
different intestinal and renal epithelial cells. As already allud-
ed to, they are able to transport their substrates against their
concentration gradients, by using the energy provided by the
inwardly directed Na+ electrochemical gradient generated by
the Na+/K+-ATPase. Their transport process follows the so-
called alternating access model [73], which means that the
substrate binding site is alternately exposed to both sides of
the plasma membrane (Fig. 2). Given the positive charge of
the Na+ ions, the transport process is electrogenic, and there-
fore, induces depolarization of the plasma membrane resting
potential. Thus, electrophysiological methods have been
widely used to characterize the functional properties of these
transporters [71]. These and other functional studies, together
with the structural information obtained from the homolog
vSGLT from Vibrio parahaemolyticus [40], have revealed
the mechanistic details of the transport cycle of these trans-
porters [31] and uncovered a kinetic model for the well-
studied SGLT1 [202].
SLC5A1/SGLT1
According to the latest version of this kinetic model for
SGLT1 (Fig. 2) [202], there are five different steps within
the transport cycle. In the first step, 2 extracellular Na+ ions
bind the protein, which leads to the opening of the first of the
two proposed structural gates, the external gate, allowing the
transit of a glucose molecule through the external vestibule to
a binding site located within the core of the protein (step 2).
When both Na+ and glucose are bound, the external gate
closes and the protein is in an occluded state, in which the
binding site is not accessible from either sides of the mem-
brane (step 3). In step 4, the inner gate opens, allowing the
release of glucose and Na+ through the internal vestibule to the
cytosol. Finally, to complete the transport cycle, the empty
transporter returns to the initial conformation (step 5). This
transport cycle has been shown to be reversible, and the di-
rection and transport rate is dependent on the transmembrane
concentration gradients of Na+ and the electric potential [133].
There is asymmetry in sugar kinetics and specificity between
the forward and reverse transport modes, in line with the phys-
iological role of the transporter to accumulate sugars within
the cells [39]. As previously mentioned, the transport stoichi-
ometry is 2 Na+:1 glucose per cycle for SGLT1, which has
been determined by measuring the reversal potential of the
transport-induced currents [21] and combining electrophysio-
logical and radiotracer flux measurements [76, 102]. It is re-
markable that in the absence of glucose, there is a specific
Na+-leak current through SGLT1, indicating that this protein
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can also function as a Na+ uniporter. Moreover, it has been
shown that SGLT1 can transport water passively. However,
while the Na+ uniport requires conformational changes and is
saturable, water permeation shows a behavior similar to water
channels [98]. Interestingly, water permeation through
SGLT1 is independent of Na+ and glucose concentration gra-
dients, but can be blocked by phlorizin. This property has been
recently validated experimentally, since it has been shown that
water permeability through SGLT1 can be altered bymutating
residues lining the sugar transport pathway [213]. Likewise, it
has been shown that SGLT1 can transport urea, which is
achieved through the same pathway as the water molecules
[213]. In terms of the physiological roles of these permeabil-
ities, as stated by the authors [213], the water permeability of
SGLT1 is orders of magnitude lower than that of aquaporins,
which may be partially corrected by the high density of the
transporters in the intestinal brush border membrane.
Likewise, the precise physiological role of SGLT1-mediated
urea transport requires further examination. Another feature of
the SGLT1-mediated transport mechanism that has been stud-
ied in detail is its pre-steady state kinetics. The transient move-
ments of the transporter generate electric currents, which re-
flect the Na+ binding/release and/or the movement of charged/
polar residues within the electrical field across the membrane
in response to changes in the resting membrane potential of
the cell [65, 66]. Electrophysiological studies revealed that the
SGLT1 pre-steady state currents are blocked by external
phlorizin and glucose, and that they are Na+-dependent, which
indicates that Na+ binds the transporter in the absence of the
sugar [65, 99]. As a consequence of the Na+-dependence of
the pre-steady state movements, the distribution of the confor-
mations of the SGLT1 population in the membrane reflects the
availability of external Na+ [71].
SLC5A2/SLGT2
As already noted, the relatively low functional activity of
SGLT2 expressed in oocytes or cultured cells somewhat lim-
ited the study of the functional properties of this protein.
Nevertheless, the studies clarified that SGLT2 corresponds
to the previously described and long-awaited low-affinity
high-capacity transporter of the kidney proximal tubule S1
segments [76]. Using expression studies in X. oocytes, it
was demonstrated that human SGLT2 mediates saturable
Na+-dependent and phlorizin-sensitive transport of D-
glucose and α-MD with Km values of 1.6 mM for α-MD
and ~ 250 to 300 mM for Na+, consistent with the previously
reported low affinity Na+/glucose cotransport. In contrast to
SGLT1, SGLT2 did not transport D-galactose. By comparing
the initial rate of 14C-α-MD uptake with the Na+ influx cal-
culated from α-MD-evoked inward currents, it was shown


















































Fig. 2 Na+-glucose cotransporter
SGLT1 kinetic model.
Extracellular Na+ binds first to the
Na+1 andNa
+
2 binding sites of the
empty carrier (states #1 and #2).
This opens the external gate,
allowing glucose to bind to the
central pocket, whereupon the
outer barrier closes to form the
occluded state (#3). The internal
barrier opens and the two Na+
ions and glucose can exit to the
cytoplasm via the aqueous inner
vestibule (#4). The transport cycle
is then completed (#5) and the
empty carrier returns to its
original state (#1), ready for the
next transport cycle. The transport
rate of SGLT1 depends on the rate
of the conformational changes
needed to open and close the outer
and inner barriers (step #2 to #3
and step #3 to #4, respectively)
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Using combined in situ hybridization and immunocytochem-
istry with tubule segment-specific marker antibodies, it was
demonstrated that there is an extremely high level of SGLT2
message in proximal tubule S1 segments [76]. Subsequent
studies, using HEK293T cells as an expression system, were
in agreement with these findings. In addition, the affinity for
D-glucose was determined and the Km was 5 mM, confirming
the low affinity of SGLT2 [71]. Phlorizin turned out to be a
more potent inhibitor of SGLT2 (IC50 = 11 nM) than of
SGLT1 (IC50 = 140 nM). As presented later in this review
(see the “SGLT2 regulation” section), a recent study demon-
strated that co-expression of SGLT2 together with the protein
MAP17 greatly increases SGLT2 functional activity [23, 24].
SLC5A4/SGLT3
When expressed in X. oocytes, SGLT3 did not show any
ability to transport glucose despite being correctly inserted in
the plasma membrane. As already mentioned, glucose was
able to induce depolarization of the membrane potential of
the SGLT3-expressing oocytes, which was reversible and
inhibited by phlorizin. These electrophysiological properties
indicated substrate selectivity among the different sugars test-
ed, and only glucose and α-MG induced currents, albeit with
very low affinity (K0.5 = 20mM). The authors highlighted that
no sugar-induced currents were observed in the absence of
Na+, but currents were significantly increased by lowering
the pH levels, suggesting permeation of H+ through SGLT3.
Furthermore, due to the low activation energy when measur-
ing the temperature dependence of the currents, the authors
suggested that SGLT3 shares more similarity to ion channels
than transporters [35]. Studies of the substrate selectivity of
SGLT3 revealed that substrate binding happens with very low
affinity, with Km values ranging from 19 to 43 mM. In con-
trast, SGLT3 exhibited high-affinity for imino sugars, withKm
values ranging from 0.5 to 9 μM. Moreover, the later study
revealed that phlorizin inhibits sugar-induced currents through
SGLT3 (Ki = 0.12 mM) and hyperpolarized the membrane
potential in the absence of sugar, suggesting a possible Na+-
leak current through SGLT3 [190]. Strikingly, the mutation of
a single amino acid converted SGLT3 into a sugar transporter
with functional properties similar to those of SGLT1.
Specifically, replacement of glutamate in position 457 by glu-
tamine, the amino acid present in the homologous position for
SGLT1 and SGLT2, turned SGLT3 into a transporter with
broad selectivity for sugars, with much higher affinity for
glucose, α-MG, and phlorizin, and a stoichiometry of 2
Na+:1 substrate. Furthermore, these studies pointed out the
high conductance of H+ at acidic levels, and again posed the
question of whether SGLT3 behaves like a cation uniporter or
a channel-like transporter [12]. In order to understand the
function of SGLT3 better, several studies have been conduct-
ed with rodent SGLT3 isoforms. Some of these proteins also
acted as “glucose sensors.” However, significant differences
were observed regarding response to sugars, phlorizin, and H+
[165]. Moreover, initial studies with the porcine SGLT3 indi-
cated that this isoform acts as Na+-coupled glucose transporter
[34]. Overall, as already noted in the previous section, there is
no consistency for the functional properties of SGLT3 among
species, and further studies are needed to reveal the in vivo
functional properties.
SLC5A9/SGLT4
Regarding SGLT4, there is only a single study describing the
functional properties of this protein, and while it provides
information about the substrate selectivity, as already de-
scribed above, the description of the putative transport mech-
anism is limited to the mentioning of the Na+-dependence of
the transport process [171].
SLC5A10/SGLT5
Similarly, initial studies with SGLT5 defined its substrate se-
lectivity and showed that the transport process was Na+-de-
pendent [58]. In addition to that, a more recent study revealed
that SGLT5-mediated sugar transport is electrogenic, sensitive
to voltage, and the authors proposed a Na+:glucose coupling
ratio of 1:1. Moreover, it was shown that in the absence of
Na+, H+ could also drive glucose transport, even though to a
lower extent. It is also interesting to mention that no pre-
steady state currents were observed for SGLT5 [51]. As al-
ready noted, this transporter is of particularly interest in the
context of the FDA-approved test to diagnose blood sugar
levels in diabetes patients, which measures the plasma level
of the metabolite 1,5-AG, since SGLT5 is likely responsible
for the reabsorption of 1,5-AG in the proximal tubule of the
kidney, and the transport is inhibited by glucose in response to
hyperglycemia.
SGLT1 and SGLT2 in transepithelial sugar
transport in the intestine and kidney
In the small intestine (duodenum, jejunum), dietary carbohy-
drates are hydrolyzed to monosaccharides by pancreatic en-
zymes and brush-border hydrolases such as lactase and su-
crase-isomaltase, resulting in high sugar concentrations on
the brush border surface after a carbohydrate-rich meal. The
digestion products are primarily D-glucose, D-galactose, and
D-fructose, which must be efficiently absorbed by mature
enterocytes in the upper one-third of intestinal villi, to avoid
osmotic imbalance, as presented in Fig. 3a. In the kidney, D-
glucose is freely filtered at the glomerulus and almost
completely extracted from the tubular fluid by the proximal
tubule transporters SGLT2 and SGLT1 (Fig. 3b), and returned
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to the blood. Approximately 90% of the filtered glucose is
reabsorbed by the early S1 segment of the proximal tubules,
and only a smaller fraction reaches the proximal straight tu-
bule (later part of S2 segments and all of the S3 segments). As
already noted, transport of each glucose molecule is coupled
either to the cotransport of two Na+ ions (SGLT1) or one Na+
ion (SGLT2) (Fig. 3). Once inside the cell, glucose can diffuse
into the blood via GLUT2 [109]. The Na+/K+-ATPase [163],
located in the basolateral membrane, pumps Na+ out of the
cell to maintain the inwardly directed Na+ electrochemical
gradient required to drive uphill glucose transport across the
brush border membrane. The high-affinity low-capacity Na+-
glucose cotransporter SGLT1 is expressed in the small intes-
tine, whereas expression of the low-affinity high-capacity
Na+/glucose cotransporter SGLT2 is almost exclusively re-
stricted to the early proximal tubule S1 segment of the kidney
(besides some expression in pancreas and cancer tissues). In
the intestine, it is the “low-capacity high-affinity” SGLT1 that
mediates rapid uptake of glucose and galactose. Despite its
“low capacity,” uptake of large amounts of sugar is warranted
by the immense expansion of the absorptive area provided by
the intestinal villi and microvilli, giving rise to an SGLT1-
expressing membrane surface of about 200 m2. Whereas D-
glucose and D-galactose are absorbed in the intestine by the
Na+/glucose cotransporter SGLT1, D-fructose is transported
across the apical membrane by the facilitated fructose
transporter GLUT5 (SLC2A5), followed by basolateral exit
via GLUT2 (SLC2A2). Alternatively, fructose may exit via
GLUT5, shown to be expressed in the basolateral membrane
as well [14]. In addition to the absorptive roles of the Na+/
glucose cotransporters, their activity also enables water ab-
sorption. This occurs through the paracellular route via sol-
vent drag across GAP junctions. In addition, SGLT1 trans-
porters themselves were shown to contribute to some extent
toward transcellular water transport in the intestine [213]. In
the kidney proximal tubules, reabsorption of about 2/3 of the
filtered water occurs via the transcellular route where it is
ensured by the expression of the aquaporin AQP1 in both
the apical and basolateral membranes [127], while only a
smaller part is absorbed through the paracellular route.
Sodium that enters the epithelial cell through Na+-coupled
transport is pumped out of the epithelial cells into the blood
via the basolateral Na+/K+-ATPase. It is this resulting
transepithelial Na+ flux that generates the osmotic gradient
necessary to drive the fluid absorption. Thus, the presence of
luminal transport of glucose, galactose, and other solutes
absorbed via Na+-coupled transport in intestine and kidney
stimulates transepithelial salt and water absorption. In the in-
testine, crypt and villus cells cooperate during digestion to
cycle fluid from the blood to the intestinal lumen and back
again. Crypt cells extrude Cl− through apical Cl− channels into














































Fig. 3 Na+/glucose cotransporters in the intestine (a) and kidney (b).
SGLT1, Sodium Glucose Cotransporter (gene name: SLC5A1).
SGLT2, Sodium Glucose Cotransporter (gene name: SLC5A2).
GLUT2, “Facilitated” (passive) Glucose Transporter (gene name
SLC2A1). GLUT5, “Facilitated” (passive) Glucose Transporter (gene
name SLC2A5). SGLT1 is expressed in the brush border membrane of
enterocytes and in the apical membranes of kidney of epithelial cells of
the proximal straight tubules (second part of S2 segments and all of S3
segments). SGLT2 is expressed in the apical membranes of the kidney
early proximal tubule cells (segment S1). GLUT2 is expressed in the
basolateral membranes of intestine and renal proximal tubule S1 cells.
In kidney proximal tubule S3 segments, cytosolic glucose exit occurs via
basolateral GLUT1. In the intestine, in the absence of GLUT2, the current
concept is that an alternative basolateral exit pathway exists, according to
which glucose is converted to glucose-6-phosphate, which is transported
into vesicles, followed by exocytosis [168]. GLUT5 is expressed in both
apical and basolateral membranes of intestinal cells
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conductance regulator, CFTR), triggering release of Na+ and
water [173]. Villus cells pump Na+ back into the space be-
tween cells via the coordinated action of Na+-coupled
cotransporters and Na+/K+-ATPase. Disturbance of
transepithelial glucose uptake in the intestine has significant
implications in the context of fluid absorption: defects in
SGLT1 in patients with the rare genetic disorder GGM
(OMIM #606824) have severe diarrhea [201]. Likewise, pa-
tients with renal glucosuria (SGLT2 defect) have moderate
diuresis that is partially compensated by SGLT1 in the prox-
imal tubule S3 segments [120].
The in vivo importance of SGLT1 and GLUT2 in intestinal
glucose absorption and renal reabsorption was studied in great
detail using Slc5a1−/− and Slc2a2−/− single or double knockout
mice. In addition, positron emission tomography (PET) using
18F-labeled glucose analogs with unique transport specificities
for GLUTs and SGLTs was employed to analyze these knock-
out animals [149, 150]. The conclusions from these investiga-
tions are presented below. Further insights were derived from
clinical data of patients with (1) GGM harboring different
missense mutations in the SGLT1 gene [19, 201] (OMIM
*182380), (2) GLUT2 deficiency (OMIM #227810), also
known as Fanconi-Bickel syndrome (FBS), a rare disorder
of glucose homeostasis that leads to accumulation of glycogen
in the liver and kidney, glucose, and galactose intolerance [38,
104], and (3) familial renal glucosuria due to missense muta-
tions in the SGLT2 gene (OMIM #233100) [109, 174]. What
follows is a list of three major conclusions that can be drawn
from both the studies with the transgenic mice and the clinical
observations:
SGLT1 is required for rapid glucose and galactose
uptake in the intestine
This finding was revealed by the PET studies of Slc5a1−/−
mice [150]. Furthermore, it is consistent with the severe diar-
rhea in affected infants with GGM: feeding breast milk or
regular infant formulas leads to life-threatening dehydration
due to luminal accumulation of glucose and galactose, where-
as fructose-based formulas that do not contain glucose or ga-
lactose are tolerated. Interestingly, in the absence of SGLT1,
the absorption of the oral glucose load delivered to the small
intestine was not completely abolished and there was slow
absorption through an as yet unknown mechanism [150].
GLUT2 is dispensable in the intestine with respect to
glucose and galactose absorption but essential for
glucose reabsorption in the kidney and glucose
transport into and out of the liver
Evidence comes from the findings that FBS patients [109]
exhibit the same phenotype as Slc2a2−/− mice [149], i.e. in-
testinal glucose absorption in both the patients and the
knockout mice was not impaired in the absence of GLUT2
[109], and that there is renal glucosuria, confirming the im-
portant role of GLUT2 in the kidney proximal tubules. How is
then glucose absorbed across the intestinal basolateral mem-
branes in the absence of GLUT2? The current notion is that
basolateral glucose exit alternatively occurs via glucose phos-
phorylation, whereupon resulting glucose-6-phosphate is
transported into the ER, followed by exit via membrane exo-
cytosis [109]. This mechanism is analogous to the alternative
pathway for glucose release from hepatocytes in the absence
of GLUT2 [59]. Evidence for this stems from transepithelial
glucose transport measurements of the intestine of Slc2a2−/−
mice [168].
Interestingly, it has recently been proposed that GLUT2
can also be targeted to the intestinal BBMwhere it would play
an important role in intestinal sugar absorption [79], and that
at very high luminal glucose concentration (e.g. 30 mM or
higher), GLUT2 is recruited to the BBM, facilitating addition-
al, SGLT1-independent apical glucose uptake [56]. However,
as noted above, the subsequent studies with Slc5a1−/− and
Slc2a2−/− mice, and the findings in patients with SLC2A2
transporter defects indicate that such a role for GLUT2 in
the BBM is unlikely under normal physiological conditions
[139].
SGLT1 and SGLT2 are essential for glucose
reabsorption in the kidney
The indispensability of these transporters was demonstrated
by the measurement of 24 h glucose excretion in Slc5a1/
Slc5a2 double knockout mice [130, 184]. In these mice, the
entire filtered glucose load was excreted in the urine, while in
the single SGLT2 or SGLT1 knockout mice, 67% and 98% of
the filtered glucose load was reabsorbed, respectively. This is
consistent with the phenotype of patients with SLC5A1 and
SLC5A2 defects. Patients with defects in SGLT2 have
glucosuria and excrete less than 50% of the filtered glucose
load, while those with defects in SGLT1 have only mild
glucosuria. Thus, in both rodents and human, the low-
affinity high-capacity glucose transporter SGLT2 reabsorbs
the bulk of the filtered glucose load in the proximal tubule
S1 segments with GLUT2 in the basolateral membrane
[207], whereas the high-affinity low-capacity glucose trans-
porter SGLT1 reabsorbs the remaining glucose molecules
from the filtrate in the late proximal tubule, with predominant-
ly GLUT1 in the basolateral membrane [66, 76, 92, 149, 184,
207].
SGLT2 emerges as an attractive therapeutic target for
diabetes treatment
Confirmation of the physiological importance of human
SGLT2 was provided by the finding that the mutations of
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the SGLT2 gene cause familial renal glucosuria [186].
Because the loss-of-function mutations of SGLT2 resulted in
the urinary excretion of glucose, SGLT2 was confirmed to be
the transporter involved in the renal reabsorption of glucose.
Further validation that SGLT2 is the high-capacity transporter
responsible for the reabsorption of the majority (90%) of glu-
cose filtered at glomerulus came from the knockout mouse
study in which the SGLT2 gene was disrupted [184]. The
renal excretion of the glucose was much higher in SGLT2
knockout mice than that in the mice with the knockout of
SGLT1 expressed in the distal straight portion (later part of
S2 segments and all of S3 segment) of renal proximal tubules,
which is involved in 10% of glucose reabsorption [78, 184].
The micro-puncture of the tubular fluid from the proximal
tubules of knockout mice, furthermore, revealed that SGLT2
knockout almost completely abolished the glucose reabsorp-
tion in the proximal portion of proximal tubules, whereas in
wild-type mice, ~ 90% of filtered glucose was reabsorbed
[184]. This finally established that SGLT2 is the transporter
responsible for high capacity glucose reabsorption that has
been proposed to occur at the proximal portion of renal prox-
imal tubules. These findings unmasked SGLT2 as an attrac-
tive target for the treatment of diabetic patients. Diabetes en-
hances renal glucose reabsorption by increasing the tubular
glucose load and the expression of SGLT2, which maintains
hyperglycemia. Inhibitors of SGLT2 enhance urinary glucose
excretion and thereby lower blood glucose levels in type 1 and
type 2 diabetes [47].
Regulation of SGLT2 expression
It has been a long-standing question why SGLT2 does not
induce a high level of functional activity when expressed in
an exogenous expression systems such as X. oocytes or mam-
malian cultured cells, where only about a 1.5- to 3-fold in-
crease in α-MG uptake could be achieved by expression of
SGLT2, compared with control oocytes [76, 207]. This low
expression level in heterologous expression systems has ini-
tially slowed down the development of specific inhibitors for
SGLT2 as therapeutic lead compounds for the treatment of
diabetes. Since SGLT2 has been identified as the transporter
that corresponds to the previously described low-affinity/
high-capacity glucose reabsorptive pathway of the renal prox-
imal tubule S1 segments, there has been an argument that the
low functional activity of SGLT2 in the exogenous expression
systems contradicts its proposed role in high-capacity glucose
reabsorption.
Given that SGLT2 alone expressed in heterologous expres-
sion systems did not exhibit high levels of glucose uptake
activity, unlike SGLT1 [42, 67, 76, 207], it has been proposed
that for the full functional expression of SGLT2, an additional
protein is required, which is not expressed in the exogenous
expression systems but present in renal proximal tubules.
Such a protein has indeed been successfully identified by
functional expression cloning in which SGLT2, together with
cRNA of clones from a cDNA library from kidney was co-
expressed in X. oocytes [23]. Following screening, the protein
identified was an integral membrane protein with two mem-
brane spanning domains, designated as MAP17 (Fig. 4a). As
show in the figure, it interacts with PDZK1, a scaffolding
protein that was shown to interact with other membrane trans-
porters [53]. MAP17 increased glucose uptake activity of
SGLT2 in RNA-injected X. oocytes by two orders of magni-
tude [23] (see Fig. 4b).
A database search revealed another protein namedMARDI
(also called small integral membrane protein 24, SMIM24)
structurally related to MAP17 [23]. Similar to MAP17,
MARDI highly augmented SGLT2-mediated glucose uptake
when co-expressed with SGLT2 [23]. The importance of
MAP17 to maintain SGLT2 function in the renal proximal
tubules under physiological condition was further confirmed
in a patient of renal glucosuria, in which SGLT2 did not show
any identifiable mutations. This patient was carrying a homo-
zygous mutation in the MAP17-coding gene [23]. Among 60
individuals with familial renal glucosuria, one patient without
identifiable mutations in SGLT2 displayed homozygosity to a
splice mutation in the coding region of MAP17. With this
finding in hand, the same research group performed an in-
depth functional characterization of SGLT2/MAP17 using
X. oocytes as an expression system. In agreement with previ-
ous findings, the experiments confirmed that SGLT2 is a high-
ly selective low-affinity glucose transporter (Km = 3.4 mM). It
has a transport stoichiometry of 1:1 and shows a 10-fold
higher affinity for phlorizin than SGLT1. Furthermore, elec-
trophysiological recordings showed that SGLT2 has little pre-
steady state and Na+-leak currents, and they described a com-
petitive inhibitory mechanism for the SGLT2 inhibitors
phlorizin and dapagliflozin [23].
Although the mechanisms through which MAP17 and
MARDI enhance glucose transport activity of SGLT2 have
not been fully clarified at the moment, it is intriguing that
MAP17 did not change the quantity of SGLT2 protein in the
exogenous expression systems [23]. Therefore, some direct or
indirect effect of MAP17 on SGLT2, which is not due to
membrane targeting or stabilization of the SGLT2 protein,
must be involved in this high augmentation of transporter
function. It was proposed that the protein conformation of
SGLT2 must be somehow affected because the co-
expression withMAP17 significantly increased both phlorizin
binding and α-MG transport [23]. In terms of protein-protein
interactions, MAP17 and MARDI are both PDZ-binding pro-
teins with a typical PDZ-binding motif at their C-termini and
that can interact with PDZ protein PDZK1 (see Fig. 4a, right
part). This interaction (e.g., with other membrane trans-
porters), however, was not essential for the stimulation of
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SGLT2 activity, because the deletion of the PDZ-binding mo-
tif of MAP17 did not affect MAP17’s augmentation of
SGLT2 activity [23].
Upregulation of SGLT2 expression under diabetic
conditions and consequences for diabetic
nephropathy
Under diabetic conditions, SGLT2 expression in proximal tu-
bules is increased [115]. Growth and hypertrophy of the dia-
betic kidney may be the trigger for a general increase in the
transport machinery in the proximal tubule under diabetic
conditions, and it may be exacerbated with advanced nephrop-
athy, when nephrons are lost and surviving nephrons try to
compensate. Increased diabetic blood glucose levels enhance
the amount of glucose filtered, provided that GFR is pre-
served, and renal glucose reabsorption is increased both due
to the increase in glucose concentration in the glomerular fil-
trate and an increase of glucose transport capacity, thereby
generating a substantial tubular glucose load [210]. Notably,
in the early phase of diabetes, GFR is often enhanced, leading
to glomerular hyperfiltration and further exacerbation of the
tubular glucose load. It was also shown that maximum renal
glucose reabsorptive capacity (TmG) is elevated in patients
with type 2 diabetes (T2D) [1].
While diabetes typically elevates glomerular filtration and
tubular glucose reabsorption, it additionally activates renal
gluconeogenesis, thereby further exacerbating the hypoglyce-
mia. This may be caused by (1) diabetes-related metabolic
acidosis that causes renal gluconeogenesis due to the
conversion of glutamine to glucose in the proximal tubule
epithelial cells, with generation of ammonia and bicarbonate,
to compensate the acidosis (for review see [77]), and (2) acti-
vation of the sympathetic nervous system in diabetes followed
by renal stimulation of gluconeogenesis via epinephrine. All
these factors give rise to a vicious circle that further nourishes
hypoglycemia and hyperfiltration. The kidney’s safety fea-
ture, however, limits hyperglycemia by excretion of glucose
in the urine, once blood glucose loads exceed TmG.
Nonetheless, the diabetic kidney will undergo pathological
alterations due to excessive metabolism of glucose in the tri-
carboxylic acid which generates enhanced oxidative stress, as
well as glomerular and tubulointerstitial damage. This is
followed by nephropathy with loss of nephrons, while surviv-
ing nephrons are trying to compensate.
SGLT2, which is responsible for the majority of glucose
uptake in early proximal tubules, is upregulated in diabetes,
but the mechanism of regulation of SGLT2 has not yet been
fully established. The following pieces of information are
available that help assemble the puzzle:
i. The regulation of expression of SGLT2 in T2D was inves-
tigated in Zucker rats. It was shown that SGLT1 and
SGLT2 mRNA levels in Zucker diabetic obese rats were
1.6- and 4.8-fold higher than in age-matched leans, respec-
tively [169].
ii. A similar observation was reported using human tubular
epithelial cells collected from the urine of patients with
T2D and maintained under cell culture conditions. The
mRNA and protein levels of SGLT2 and also GLUT2
SGLT2 MAP17






Fig. 4 MAP17 model and augmentation of SGLT2 function. a Model
showing MAP17 activating SGLT2 (and possibly other transporters like
NHE3), via an unknown mechanism, independent of the PDZ transporter
complex formation. bAugmentation of SGLT2 functional activity by co-
expression with MAP17. The cRNAs for human SGLT2 and human
MAP17 were obtained by in vitro transcription and injected individually
or co-injected into X. oocytes. The uptake of 14C-α-MG (50 μM) was
measured in ND96 buffer with 1 mM mannose 1 mM galactose [23] for
2 h and expressed as pmol/oocyte/h. The co-expression of MAP17 dras-
tically increased SGLT2-mediated 14C-α-MG uptake. The experiment
shown in Fig. 4b was performed by Ryuichi Ohgaki and Jin Chunhuan,
Department of Bio-system Pharmacology, Graduate School of Medicine,
Osaka University (unpublished data from the laboratory of Yoshikatsu
Kanai)
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were significantly increased in the epithelial cells obtain-
ed from diabetic patients compared with those from nor-
mal subjects [135]. Accordingly, sugar uptake was in-
creased in the cells from diabetic patients.
iii. The high level of glucose itself did not affect SGLT2
expression in tubular cells but insulin significantly in-
creased tubular SGLT2 levels through the generation of
oxidative stress [110]. Because hyperinsulinemia is ac-
companied with the onset and early stage of T2D [80],
the upregulation of SGLT2 at least at the early stage of
T2D thus could be due to the stimulation by insulin.
Indeed, increased glucose absorption in proximal tubule
membrane vesicles of hypertensive rats was found to be
due to induction of SGLT2 expression leading to kidney
damage due to the generation of reactive oxygen species
(ROS) [137]. Increased SGLT2 expression in the diabet-
ic condition may lead to kidney damage via the produc-
tion of reactive oxygen species.
iv. HNF1α was shown to control renal glucose reabsorption
in mouse and human. It was demonstrated that HNF1α
controls SGLT2 expression by direct transcriptional acti-
vation, whereas SGLT1 and GLUT2 were not affected
[129]. In addition, it was shown that renal proximal tubu-
lar reabsorption of glucose was reduced in patients with
maturity onset diabetes of the young type 3 (MODY3)
that is caused by mutations of the HNF1α gene.
v. In addition, it was shown, based on studies with db/db
mice with diabetes and high-glucose-cultured porcine
PT LLC-PK1 cells in a two-chamber system treated with
the SGLT2 inhibitor canagliflozin, that SGLT2 expres-
sion was stimulated by basolateral high glucose concen-
trations through activation of the so-called GLUT2/
importin-α1/HNF-1α pathway, while the expression of
the NAD+-dependent protein deacetylase SIRT1 de-
creases, leading to a deficiency of autophagy [179].
Upregulation of SGLT2 expression in diabetes may be
caused through sensing of basolateral hyperglycemia via
GLUT2 [111, 119]. Interestingly, SGLT2 inhibitors in-
duce SIRT1, together with adenosine monophosphate-
activated protein kinase AMPK, which have been shown
to stimulate autophagy, thereby ameliorating cellular
stress and glomerular and tubular injury [121].
vi. It was reported that mTOR signaling is involved in the
upregulation of the expression of nutrient transporters,
including SGLT2, in renal proximal tubule cells. The
combination of the deletions of the mTOR complex 1
(mTORC1) and 2 (mTORC2) by the conditional knock-
out of the regulatory associated protein of mammalian
target of rapamycin (RAPTOR), which is an essential
component of mTORC1, and the rapamycin-insensitive
companion of mammalian target of rapamycin
(RICTOR), which is essential for mTORC2, resulted in
the development of a Fanconi-like syndrome involving
glucosuria in mice [57]. Interestingly, proteomics and
phosphoproteomics of freshly isolated kidney cortex
identified either reduced expression or loss of phosphor-
ylation at critical residues of nutrient transporters, which
leads to reduced nutrient transport due to perturbation of
the endocytotic machinery. For example, phosphoryla-
tion of mouse Sglt2 at S623was reduced in kidney cortex
by the loss of mTORC1 [57]. This phosphosite is highly
conserved between species, including human SGLT2
(S624) [50]. It was shown that the phosphorylation at this
site increases membrane insertion of SGLT2 and en-
hances glucose transport [50]. The loss of phosphoryla-
tion at S623 was, thus, proposed to explain the glucosuria
caused by the mTORC1/mTORC2 deletion.
vii. It remains to be determined, whether the scaffolding
protein MAP17 is involved in the functional upregula-
tion of proximal tubule transporters such as SGLT2 and
also NHE3 (SLC9A3). Both of these transporters are
stimulated by insulin to enhance Na+ and glucose reab-
sorption [83, 110], but a role ofMAP17 in the regulation
of SGLT2 and other relevant transporters in the diabetic
conditions has not been reported thus far.
In conclusion, further studies will still be needed to fully
understand the mechanisms of upregulation of both SGLT2
and GLUT2 in the different diabetic conditions.
Regulation of SGLT1 in the kidney
in the absence of SGLT2
SGLT2 inhibition shifts glucose uptake further downstream
toward S3 segments and thick ascending limbs (TAL). In the
kidney, SGLT2 and SGLT1 account for at least 90% and
about 3% of fractional glucose reabsorption (FGR), respec-
tively, while euglycemic individuals treated with an SGLT2
inhibitor maintain an FGR of 40–50% [138]. This value is
similar to the values of Sglt2 knockout mice [130]. The in-
crease of the contribution of SGLT1 toward glucose reabsorp-
tion following SGLT2 inhibition was studied in mice [138].
Selective SGLT2 inhibition in mice revealed that SGLT2 and
SGLT1 account for renal glucose reabsorption in euglycemia,
with 97 and 3% being reabsorbed by SGLT2 and SGLT1,
respectively. However, when SGLT2 is fully inhibited by an
SGLT2-inhibitor, there is an increase in SGLT1-mediated glu-
cose reabsorption which explains why only 50–60% of fil-
tered glucose gets excreted [138]. Thus, when SGLT2 func-
tion is lacking, either due to SGLT2 inhibition or lack of gene
expression in Sglt2−/− mice or in patients with familial
glucosuria, there is significant compensation by SGLT1. An
olfactory G protein-coupled receptor, Olfr1393, expressed in
the kidney proximal tubule was proposed to serve as a phys-
iological regulator of SGLT1 expression [138]. Alternatively,
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the G protein-coupled glucose-sensing receptor T1R3 that
was originally identified in sheep and rodent intestine [106,
158] might also be a candidate for SGLT1 regulation in kid-
ney proximal tubules as well [215]. However, the precise
mechanism by which renal SGLT1 is upregulated to compen-
sate for the lack of SGLT2 function still awaits further
investigation.
Structural biology; molecular modeling;
SGLT1 and SGLT2; molecular architecture
Proteins of the SSS family usually contain 10–14 transmem-
brane helices (TMHs), and the tertiary structures of two rep-
resentative members are known. The sodium/galactose
symporter from Vibrio parahaemolyticus (vSGLT) was crys-
tallized with bound galactose in an inward-open conformation
(PDB ID: 3DH4) [40]. The structure of the inactive mutant
variant K294A has also been solved and displays a very sim-
ilar inward-open conformation in the absence of the bound
sugar (PDB ID: 2XQ2) [194]. In addition, another protein
from the same family, the sialic acid transporter SiaT from
Proteus mirabilis, was crystallized in the presence of sialic
acid (N-acetylneuraminic acid) (PDB ID: 5NV9) [192].
Interestingly, this structure features the protein in an
outward-open conformation.
The above structures show that SSS transporters share the
same structural fold as APC (amino acid-polyamine-
organocation) transporters, featuring a transporter core formed
by 5 + 5 TMHs in an inverted repeat arrangement. Strikingly,
a bound Na+ ion was also observed in the structures of vSGLT
and SiaT in a location analogous to the “Na2” cation-binding
site present in many APC-fold transporters [25, 125, 126, 161,
204], indicating the conservedness of the Na2 site across the
structural superfamily. Many APC-type transporters with a
2:1 cation:solute transport stoichiometry also feature a second
cation-binding site (termed “Na1”), which is typically closer
to the substrate-binding pocket. However, the SiaT structure
suggests that a second Na+ ion binds to a distinct (third) site,
termed “Na3,” implying that the Na1 site found in other APC-
type transporters is not conserved in the SSS family [192].
This is also likely to be the case for human SLC5A1.
The mechanism of transport has been extensively studied
for human SLC5A1 using a variety of methods (Fig. 2).
Experimental data have long supported a transport model
where Na+ ions bind to the protein first, followed by glucose
[122]. Initial binding of Na+ is expected to occur to the Na2
site (termed “Na+2” in Fig. 2), then quickly jump to the Na3
site (“Na+1” in Fig. 2) [192]. After the second Na
+ binding to
“Na+2” (Fig. 2), the two bound Na
+ ions are expected to sta-
bilize the transporter in an outward-open state and increase
affinity for sugar binding [40, 148]. Binding of sugar induces
the formation of the extracellular gate (Y87, F424, M73 in
vSGLT; F101, F453, L87 in hSLC5A1; F98, F453, L84 in
hSLC5A2, respectively) and thus extracellular closure [40].
The subsequent transition of the protein to an inward-facing
state destabilizes the Na+ bound at the “Na+2” site, and this ion
is proposed to be released on a short time scale [194]. These
rearrangements are also expected to disrupt the “Na+1” site
and cause the dissociation of Na+ bound at “Na+1” (Fig. 2).
The release of Na+ ions allows Y263 in vSGLT (Y290 in
hSLC5A1 and hSLC5A2), which was shown to be in a stack-
ing interaction with the bound sugar ring and was proposed to
be an intracellular gate residue, to adopt a different conforma-
tion and thus facilitate the dissociation of the bound sugar
[194]. Interestingly, further intracellular gating residues
R260 and D182 in SiaT, where D182 also forms part of the
“Na+1” (Na3) binding site, are also conserved in both human
SLC5A1 and SLC5A2 (R300 and D204/D201, respectively).
In the inward-open holo structure of vSGLT, the hydroxyl
groups of the bound galactose molecule make extensive
hydrogen-bond contacts with protein residues, and its hetero-
cyclic carbon ring engages in a stacking interaction with aro-
matic side-chains of the protein. To assess the structural de-
tails of sugar binding to human SLC5A2 during the early steps
of the transport cycle, we explored the binding modes of glu-
cose to an outward-open state of human SLC5A2 using a
combination of homology-based modeling and molecular
docking (Hediger et al., unpublished observation). To this
end, we have used MODELLER 9.23 [195, 196] to build
structural models of human SLC5A2 based on the structure
of SiaT (PDB ID: 5NV9) using a manually adjusted sequence
alignment more suitable for loop modeling. To account for
conformational variation, we have generated a total of 1000
protein models. We have performed molecular docking of α-
D-glucose on all 1000 protein models using AutoDock 4.2.6
[108] with flexible ligand and rigid protein side-chains. The
search space was defined as a cube of 22.5 × 22.5 × 22.5 Å
centered on the location of the galactose ring from the vSGLT
structure (PDB ID: 3DH4) after fitting to SiaT. For each mod-
el of SLC5A2, 10 docked poses of glucose were generated.
The best 500 of the resulting 10′000 glucose poses were en-
ergy minimized using SMINA [86] while keeping neighbor-
ing protein side-chains flexible, and the resulting ligand poses
rescored using the Vinardo scoring function [134]. From the
resulting set, glucose poses where the distance of the center of
the docked glucose and the original galactose ring from
vSGLT was less than 2 Å were ranked according to their
calculated binding energies. The glucose pose with the lowest
energy yielded by the above described process is shown in
Fig. 6a. Importantly, the plane of the glucose ring predicted
in our study is parallel to that of galactose observed in the
vSGLT structure, while all hydroxyl groups of the sugar li-
gand are in hydrogen-bonding orientation with protein resi-
dues. This is in contrast to a recent analogous study [13],
where the sugar was predicted to bind in a perpendicular
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orientation. Based on our model, SLC5A2 residues K321,
E99, S287, and N75 directly coordinate the sugar ligand,
whereas the stacking interaction with Y290 expected in anal-
ogy to vSGLT is absent due to steric reasons. The formation of
this interactionmight be a major driving force for the outward-
to-inward transition of the apo transporter. Importantly, our
results, also in-line with previous studies [13], explain the
deleteriousness of the naturally occurring loss-of-function var-
iant K321R associated with familial renal glucosuria [103].
However, other mutations near the sugar-binding site, such
as F98L [208, 209], A102V [18], and G77R [193], might also
cause loss-of-function in hSLC5A2 through directly interfer-
ing with glucose binding.
Interestingly, during our docking studies, we have consis-
tently observed docked glucose poses where the pyranose ring
center was ~ 7 Å away from its expected location according to
the vSGLT structure (Fig. 6f). Structural analysis of the pro-
tein environment near this region suggests a plausible sugar-
binding site, where glucose would form hydrogen-bonds with
protein residues D158, K154, Y150, Y290, and the backbone
amino and carbonyl groups of G77 and N75, respectively.
Remarkably, D158 is conserved in all 7 sugar-transporting
human SLC5 proteins, but not in non-sugar transporting
SLC5 members, while the other 3 residues are partially con-
served (K154 not in hSLC5A4, Y150 not in hSLC5A4 and
hSLC5A10, Y290 not in hSLC5A9). We believe that these
residues might form an intermediate sugar-binding site during
the sugar translocation process, but further investigation is
needed to clarify their roles in the transport process.
Development of inhibitors, analysis,
and inhibition kinetics of canagliflozin acting
on SGLT2 and SGLT1
The observation that the suppression of renal glucose reab-
sorption ameliorates diabetic conditions was first reported in
1987. To demonstrate the contribution of glucotoxicity to the
development and exacerbation of the diabetic condition,
phlorizin was administered to partially pancreatectomized di-
abetic rats with continuous subcutaneous infusion through
small implantable minipumps. In this study, it was demon-
strated that phlorizin, by increasing urinary glucose excretion,
normalized plasma glucose levels and completely corrected
abnormalities associated with the diabetic conditions such as
insulin deficiency and hyperglycemia [142]. Furthermore, the
correction of hyperglycemia with phlorizin treatment normal-
ized tissue sensitivity to insulin in the diabetic rats [142]. In
this study, phlorizin was used to normalize the blood glucose
level without mediating insulin actions to demonstrate the
contribution of glucotoxicity to diabetic conditions [142]. It
was shown that phlorizin recovered the function of β-cells
secreting insulin and ameliorated tissue insulin resistance.
Although phlorizin is a high-affinity inhibitor of Na+/glucose
transporters, it has previously not been clinically developed as
an anti-diabetic drug. One of the main reasons was that
phlorizin is not orally administrable. Phlorizin is an O-glyco-
side and, therefore, it is hydrolyzed in the intestinal lumen by
β-glucosidase and broken down into glucose and phloretin
that inhibits facilitative glucose transporters (GLUTs) [36].
The second reason was that phlorizin is less selective.
Phlorizin, in fact, inhibits both SGLT1 and SGLT2 [42].
When phlorizin is orally administered, the strong inhibition
of intestinal SGLT1 would cause severe life-threatening diar-
rhea similar to the glucose-galactose malabsorption caused by
the loss-of-function mutations of the SGLT1 gene [178].
To overcome such disadvantages of phlorizin, its deriva-
tive T-1095 was synthesized [117]. T-1095 is an orally ad-
ministrable esterified prodrug that is absorbed from the gas-
trointestinal tract and converted to an active form by the es-
terase in the liver [117]. Because it is inactive in the
lumen of the small intestine, T-1095 does not inhibit
SGLT1 in the small intestine [4]. Although the
SGLT2/SGLT1 selectivity of the active form of T-
1095 is much less than that of SGLT2 inhibitors cur-
rently in clinical use, orally administered T-1095 could
selectively inhibit renal glucose reabsorption while min-
imally affecting intestinal glucose absorption [117]. In
the pre-clinical studies, orally administered T-1095 in-
creased glucose excretion into urine in diabetic animals
and successfully decreased both blood glucose and
HbA1c levels [117]. It suppressed the postprandial hy-
perglycemia after a meal load in diabetic animals. The
hyper t r ig lyce r idemia and the deve lopment of
microalbuminuria associated with diabetic conditions
were also ameliorated [4, 117]. The results obtained
from T-1095 on diabetic animal models confirmed that
the inhibition of renal glucose reabsorption could be a
novel therapeutic approach for diabetes mellitus.
The SGLT2 inhibitors currently in clinical use include
dapagliflozin, canagliflozin, empagliflozin, ipragliflozin,
tofogliflozin, luseogliflozin, and ertugliflozin [2, 89, 113]
(see Fig. 5). Sotagliflozin has been abandoned while enrolling
into large clinical heart and kidney outcome trials. Although
these compounds have been synthesized based on the
phlorizin structure, they are C-glycosides, distinct from
phlorizin that is an O-glycoside, making sure that they are
not hydrolyzed in intestine and metabolically stable in blood
after absorption from intestine [6]. Therefore, they are admin-
istered once a day orally for the treatment of patients with
diabetes. The additional advantage of these clinically used
SGLT2 inhibitors is their high-affinity and selectivity for
SGLT2 except sotagliflozin designed as a dual inhibitor,
inhibiting both SGLT2 and SGLT1. They are 150 to ~ 3000
times more selective for SGLT2 than SGLT1 except
sotagliflozin [89].
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Physiological basis of clinical benefits of SGLT2
inhibitors
SGLT2 inhibitors came in use clinically in 2012, and a bunch
of clinical evidence had to be brought together to demonstrate
their effectiveness in the treatment of diabetic patients.
SGLT2 inhibitors reduce blood glucose and HbA1c, recover
β-cell function, and ameliorate insulin resistance. They, fur-
thermore, decrease bodyweight and blood pressure, and lower
blood urate and triglyceride levels [6]. Large-scale clinical
trials have also demonstrated that they are effective in the
suppression of cardiovascular events and renal complications
[212]. The usefulness of SGLT2-selective inhibition in the
treatment of diabetes was also confirmed in Slc5a2 knockout
mice showing that SGLT2 deletion reduced hyperglycemia
associated with high-fat diet and obesity, improved glucose
intolerance, and increased glucose-stimulated insulin secre-
tion [74]. Not only the effectiveness but also the clinical safety
of the drugs was established. It is also well recognized that the
risk of hypoglycemia is relatively low when using SGLT2
inhibitors [6].
Effects of SGLT2 inhibitors on extra-renal SGLT2
The expression of SGLT2 was originally proposed to be kid-
ney-specific, but detailed expression studies have revealed
extra-renal expression of SGLT2. In pancreatic α-cells secret-
ing glucagon, SGLT2 was shown to be expressed with
SGLT1 [15]. It was demonstrated that the SGLT2 inhibitor
dapagliflozin triggers glucagon secretion in human islets by
directly acting on islet α-cells. This may explain why SGLT2
inhibitors cause the paradoxical increase of plasma glucagon
levels [20].
The other example of extra-renal expression of SGLT2 is in
cancers. It has been demonstrated that cancer cells upregulate
glucose transporters such as GLUT1 to compensate increased
demand of glucose associated with the Warburg effect [71].
SGLT2 was also shown to be expressed in some types of
cancers such as pancreatic and prostate cancers, together with
SGLT1 [81, 153]. It is intriguing that SGLT2 inhibitors reduce
tumor growth and survival in a xenograft model of pancreatic
cancer [153].
Molecular docking of the gliflozin inhibitors of SGLT2
To elucidate the binding of gliflozins to human SLC5A1 and
SLC5A2 proteins, we have applied our computational
docking protocol described above to the generation of docked
poses of phlorizin, canagliflozin, dapagliflozin, and
tofogliflozin. The chemical structures of these compounds
are presented in Fig. 5. Based on the assumption that the sugar
moiety of these compounds should occupy the same binding
site as glucose, we have employed filtering of the resulting
poses based on the distance of the center of their pyranose
rings to that of galactose in the vSGLT structure, similarly
as we did for glucose docking. The best-scoring (the lowest
binding energy) of the resulting poses is shown in Figs. 6a–e
(Hediger et al., unpublished observation). Interestingly, the
sugar moieties of the docked inhibitors are all rotated com-
pared with the docked glucose molecule (Fig. 6a), but their
Fig. 5 Chemical structures of various inhibitors of the SLC5 proteins in
comparison with α-D-glucose. While phlorizin is a relatively non-
selective inhibitor of sodium-coupled sugar transporters, canagliflozin,
dapagliflozin, empagliflozin, ipragliflozin, luseogliflozin, and
tofogliflozin are selective (250-fold, 1200-fold, 2500-fold, 360-fold,
1650-fold, 2900-fold, respectively) inhibitors of human SLC5A2 vs hu-
man SLC5A1 (see text for details)
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rings still share a plane parallel to the membrane bilayer, sim-
ilar to glucose. A notable exception is tofogliflozin, where the
sugar moiety is sterically fixed compared with the aglycon tail
and was predicted to bind in a perpendicular orientation. For
phlorizin, which is a less selective inhibitor of both hSLC5A1
and hSLC5A2, aromatic stacking interactions are noticeable
between the aglycon tail and protein residues Y290 and F98.
This aligns well with experimental results showing that F101
in human SLC5A1 (analogous to F98 in human SLC5A2) is
important for phlorizin binding [148]. For the other 3 inhibi-
tors, their aglycon tails reach into a binding pocket lined by
protein residues Y150 and W289, which engage in aromatic
stacking interactions with the ligands. Notably, this binding
pocket is not utilized by phlorizin and its existence might be
responsible for the significantly higher selectivity of the other
3 inhibitors for hSLC5A2. While no obvious differences in
sequence can be observed in this binding pocket between
hSLC5A1 and hSLC5A2, dynamic factors such as extracellu-
lar gate opening could affect the accessibility or the size of this
binding pocket. Notably, one relevant sequence difference is
in the hinge region of the extracellular gate, where A464 in
hSLC5A2 vs G464 in hSLC5A1 could provide more rigidity
and thus a more well-formed binding pocket in the case of
human SLC5A2 compared with human SLC5A1. Another
analogous study on the selectivity of gliflozin compounds
has suggested that these highly selective compounds interact
with the C-terminal region of extracellular loop 5 (EL5)
directly through residue H268, and that their binding leads
to a partial closure of the extracellular gate [13]. The authors
argue that direct interaction with the non-conserved residue
H268 in hSLC5A2 (D268 in hSLC5A1) contributes to the
selectivity of gliflozins, augmented by the absence of the sec-
ond bound Na+ ion at the Na3 site in hSLC5A2, which shifts
the conformational equilibrium of the transporter to favor ex-
tracellular gate closure [13]. In summary, dynamic effects are
likely to be responsible for the selectivity gliflozin com-
pounds, and further crystallographic studies are necessary to
verify the precise binding modes of these inhibitors to human
SLC5A1 and SLC5A2.
Clinical benefits of the SGLT2 inhibitors
in type 1 and type 2 diabetes and role
of the renin-angiotensin system
SGLT2 inhibitors are effective glucose-lowering drugs that
primarily act by blocking the SGLT2 transporter in the renal
proximal tubule. The specific clinical benefits of the drugs are
as follows.
Body weight reducing effects of SGLT2 inhibitors
These drugs lower body weight in T2D already within a few
weeks after starting the therapy [93]. Initially, the weight loss
Fig. 6 Bindingmodes of glucose and various inhibitors to human SGLT2
(SLC5A2). The protein backbone is shown as gray ribbon. Selected
individual amino acid side-chains are shown in dark cyan. Purple sphere
represents the Na+ ion. Hydrogen bonds and aromatic ring stacking
interactions are shown as dashed lines. Docked ligands are shown in
various colors (a–e). Panel f shows a putative alternative sugar-binding
site of docked α-D-glucose (yellow) compared with the canonical binding
pose (pink) (see text for details)
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is mostly due to diuretic effect through increased osmotic
diuresis and a related decrease of the extracellular volume
[205]. However, the increased urine volume of patients was
normalized again after 4 weeks, which highlights that there is
a homeostatic adaptive mechanism [3]. This weight reduction
is accompanied by reduction of total body fat percentage due
to the negative energy balance, increased lipolysis, and fatty
acid oxidation, with simultaneous inhibition of lipogenesis
and increased formation of ketone bodies. [45, 131]. The lean
tissue mass that mainly includes the muscle mass showed no
significant change following SGLT2 inhibitor treatment in
one study [157], while in another study, the loss of muscle
mass, alongside the loss of fat mass in patients with T2D, was
observed in response to SGLT2 inhibition [82].
Nephroprotective effects
Elevation in glomerular filtration rate (GFR) is observed early
in the pathogenesis of T1D and T2D. At the single-nephron
level, diabetes-related renal hemodynamic adaptations occur
to counteract loss-of-functional nephron mass, thereby in-
creasing glomerular hydraulic pressure, a phenomenon known
as glomerular hyperfiltration, leading to irreversible nephron
damage and contributing to initiation and progression of kid-
ney disease in diabetes. Reduced GFR is one of the key
markers of predicting the risk of end-stage renal disease and
renal death in diabetes. Reported prevalence of hyperfiltration
at the whole-kidney level is 10–67% in T1D and 6–73% in
patients with T2D [175]. Hyperfiltration in T1D is thought to
precede the onset of albuminuria and decline in renal function
and to predispose to progressive nephron damage by increas-
ing glomerular hydraulic pressure and transcapillary convec-
tive flux of the ultrafiltrate carryingmacromolecules including
albumin. Increased GFR in single remnant nephrons to com-
pensate for reduced nephron numbers further accelerates renal
damage in diabetes. SGLT2 inhibitors have general
nephroprotective effects. As outlined below, in diabetes pa-
tients, SGLT2 inhibitors activate the tubuloglomerular feed-
back (TGF) mechanism with the inhibition of glomerular
hyperfiltration, which is characteristic in diabetes patients.
Beneficial effects are also anticipated for patient groups with-
out diabetes, such as chronic kidney disease (CKD) patients,
but confirmatory studies are still required.
Inhibition of glomerular hyperfiltration by SGLT2
inhibitors in patients with T1D via the
tubuloglomerular feedback mechanism
As already noted, glomerular hyperfiltration is a recognized
risk factor for the development and progression of diabetic
kidney disease (DKD). Also, it is a risk factor in the develop-
ment of chronic kidney disease in general. Hyperfiltration of
the remaining nephrons is due to activation of the renin-
angiotensin-aldosterone system (RAAS), leading to increased
systemic blood pressure, increased angiotensin sensitivity of
efferent arterioles and to tubuloglomerular feedback (TGF)
adaptation in the afferent arterioles.
In addition, Na+ reabsorption in the proximal tubules is
increased in T1D and in T2D due to chronic hyperglycemia.
As already noted, this results in the upregulation of the expres-
sion of both SGLT2 and GLUT2 [115, 135]. Thereby, Na+
(i .e . NaCl) exposure at the macula densa of the
juxtaglomerular apparatus diminishes which, due to a “renal
misinterpretation” of a “reduced effective arterial blood vol-
ume”, leads to an increased dilation of the afferent arteriole, in
order to preserve the alleged low intraglomerular pressure and
the GFR in the spirit of a correct autoregulation. This resulting
unfavorable hyperfiltration further accelerates nephron de-
struction and progression of renal failure. Clinical studies
using the SGLT2 inhibitor empagliflozin revealed that
SGLT2 inhibition significantly reduces the hyperfiltration in
patients with T1D mellitus [22]. A recent study provided the
first direct demonstration of changes in renal hemodynamic
function by SGLT2 inhibitors using in vivo glomerular visu-
alization with multi-photon microscopy in a diabetic animal
model [82]. Within 2 h after application a single dose of
empagliflozin, they observed an acute drop in hyperfiltration
and albumin excretion in the diabetic mice. At the same time,
the investigators visualized a distinct reduction of the extend-
ed diameters of the afferent glomerular arterioles. In parallel,
the amount of the excreted adenosine in the urine significantly
increased. The effect of the SGLT2 inhibitor could be
prevented when using a selective adenosine blocker, thereby
validating the hypothesis that SGLT2 inhibition leads to in-
creased adenosine production at the macula densa which ulti-
mately leads to constriction of the afferent arterioles.
The mechanism that leads to the constriction of the afferent
glomerular arterioles via the tubuloglomerular feedback
(TGF) to counteract the hyperfiltration in the diabetic condi-
tion is outlined in Fig. 7. In addition, Box 1 presents the role of
macula densa cells in controlling GFR and renin release via
TGF. As shown in Fig. 7, in T1D, inhibition of the SGLT2-
mediated Na+-coupled glucose reabsorption in the proximal
tubules results in an increase in the luminal NaCl concentra-
tion at the macula densa above the threshold value. As a result,
macula densa cells trigger the reduction of renin release to
suppress the renin-angiotensin-aldosterone system (RAAS)
and vasoconstriction of the afferent arterioles to reduce
hyperfiltration that is commonly associated with diabetes.
This is achieved via generation of extracellular adenosine in
the juxtaglomerular interstitium (see Box 1). As shown in Fig.
7, adenosine can directly act on Gi-coupled A1 receptors
expressed on afferent arteriolar smooth muscle cells [63, 87]
to trigger vasoconstriction of the afferent arterioles to reduce
GFR. In addition, adenosine causes via A1R inhibition of
renin release in juxtaglomerular cells (see Fig. 7). The latter
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is believed to occur via A1R-triggered TRPC6 channel-
mediated calcium entry, followed by calcium-mediated inhi-
bition of renin release [63]. Thus, adenosine signaling through
the TGF is of central importance in preventing diabetic
hyperfiltration via SGLT2 inhibition, leading to the
nephroprotective action of SGLT2 inhibitors, with prevention
of subsequent damage of remaining nephron segments. The
mechanism explains why in T1D, after SGLT2 inhibition,
there is an initial decrease in GFR that is independent of sys-
temic blood pressure.
Box 1 Role of macula densa cells in TGF-mediated control
of GFR and renin secretion.
Fluid flow through the kidney nephron is being kept within a narrow
range under healthy conditions for optimal maintenance of salt and
water balance. The macula densa cells control the tubuloglomerular
feedback (TGF) to fine-tune GFR [156]. As shown in Fig. 7, when the
luminal NaCl concentration at the macula densa rises, as during ECV
expansion or in response to SGLT2 inhibition, NaCl entry into macula
densa cells via NKCC2 leads to the production of adenosine. The
macula densa cells do not have enough Na+/K+-ATPases on their
basolateral surface to excrete the added Na+ taken up. This results in
osmotic swelling and the current concept is that the swelling leads to
exit of ATP across the basolateral membrane via stretch-activated,
non-selective maxi-anion channels, followed by its conversion to
adenosine via the ecto-5′-nucleotidase channels [16, 87, 143, 144].
Adenosine then interacts with adenosine 1 receptors (A1R) on vascular
smooth muscle, resulting in contraction of afferent arterioles and re-
duction of GFR (the TGF response). On the other hand, in response to
decreased luminal NaCl concentration at the macula densa (the reverse
situation illustrated in Fig. 8), i.e., in the context of reduced blood
pressure or glomerular filtration, NKCC2 transport activity is reduced,
which causes release of prostaglandin in macula densa that activates
signaling cascades to promote renin release and activation of the
renin-angiotensin-aldosterone system (RAAS). This in turn increases
the blood pressure via aldosterone by increasing renal reabsorption of
sodium and water. In addition, with luminal NaCl concentrations be-
low the threshold value, vasodilation of afferent arterioles occurs,
which increase glomerular filtration pressure and tubular fluid flow.
Recently, it was observed that macula densa cells of mouse
and human kidney also express SGLT1 where it is anticipated
to serve as a glucose sensor to further regulate TGF, whereby
glucose taken up mediates upregulation of nitric oxide (NO)
synthase NOS1, followed by generation of NO that will de-
crease TGF and promote glomerular hyperfiltration [215]. In
support of this concept, another study revealed that (1) dele-
tion of SGLT1 reduced glomerular hyperfiltration in diabetic
Akita mice but did not markedly change blood glucose levels
and (2) the increase in macula densa NOS1 expression ob-
served in diabetic Akita mice was abolished in the absence
of SGLT1 [164]. Future studies on this interesting topic will
be of great interest. Additionally, further studies on the local-
ization of SGLT1 in distal tubules would be important, be-
cause earlier reports of rat [76, 92, 207] and human kidney
[191] were not able to provide evidence for SGLT1 expres-
sion in macula densa cells. It will also be of interest to know
whether SGLT1 is upregulated in macula densa cells in re-
sponse to SGLT2 inhibition, in analogy to SGLT1 in the
proximal straight tubules.
Fig. 7 Effect of SGLT2 inhibition on renal hemodynamics via the
tubuloglomerular feedback (TGF) mechanism: the macula densa cells
are specialized epithelial cells that form the macula densa as part of the
distal tubule sensing system of the same nephron. As shown on the right,
these cells detect the luminal NaCl concentration in the tubular fluid.
NaCl detection occurs after its uptake by SLC12A1 (NKCC2). Elevated
filtration at the glomerulus or reduced reabsorption of Na+ and water in
the proximal tubule causes the tubular fluid at the macula densa to have a
higher concentration of luminal NaCl. Inhibition of SGLT2-mediated
Na+-coupled glucose transport significantly increases NaCl exposure at
the macula densa. This is followed by increased transport activity of
SLC12A1 (NKCC2) in macula densa cells. As part of the sensing mech-
anism, this ultimately leads to extracellular accumulation of adenosine in
the juxtaglomerular interstitial space (see text for details). Adenosine can
then directly act on Gi-coupled A1 receptors expressed on afferent arte-
riolar smooth muscle cells [63, 87], triggering vasoconstriction of the
afferent arterioles to reduce GFR, as shown in Fig. 8a and b
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Beneficial effects of SGLT2 inhibitors in T2D-based
and combination therapies
Glomerular hyperfiltration with elevated GFR is an im-
portant risk factor for the development of diabetic kid-
ney disease (DKD). This is also true for T2D patients,
although hyperfiltration is more difficult to diagnose,
because they often have a normal or even a reduced
GFR due to loss of nephrons. It is likely, however, that
they still exhibit hyperfiltration at the single nephron
level. Blockage of the renin-angiotensin system (RAS)
by antihypertensive agents such as ARBs (angiotensin
receptor blockers) has proven effective for the treatment
of T2D patients. ARBs improve DKD progression by
lowering glomerular pressure and hyperfiltration, mainly
by dilating efferent arterioles due to lack of constriction
[85]. In T1D, adenosine plays a central role in execut-
ing the nephroprotective response of SGLT2 inhibitors,
by ameliorating preglomerular arteriolar dilation and
hyperfiltration via the adenosine receptor A1R, acting
on the vasoconstriction of afferent arterioles. A recent
study was launched to examine the renoprotective ben-
efits of a combination therapy with the SGLT2 inhibitor
dapagliflozin in T2D patients treated with ARBs [185].
The study was undertaken because (1) it was unclear
how exactly SGLT2 inhibitors affect renal hemodynam-
ics in patients with T2D whose renal physiology differs
from that of previously studied T1D patients with
hyperfiltration and (2) it was unknown whether the ef-
fects of SGLT2 inhibitors are diminished in response to
glucose lowering. Therefore, the effects of dapagliflozin
on renal hemodynamics in T2D patients treated with the
blood sugar lowering agent metformin, together with
ARB, were examined as well. The study revealed that
the beneficial renal hemodynamic effects of SGLT2 in-
hibitors are fully independent of the glucose-lowering
effects. Interestingly, lowering GFR was accompanied
by a stable or even lowered renal vascular resistance
(RVR), suggesting that the acute decline in GFR is
mainly caused by post-glomerular vasodilation, rather
than preglomerular restriction. Interestingly, in this
study, the concentration of adenosine, which plays a
key role in mediating the positive effects of SGLT2
inhibitors, was also significantly increased in T2D pa-
tients. Compared with the hyperfiltration in patients
with T1D, however, baseline GFR and effective renal
plasma flow (ERPF) were much lower in the T2D
study, indicating that the preglomerular arteriolar diam-
eter was already narrow, thus limiting or prohibiting
further preglomerular vasoconstriction by adenosine
(see Fig. 8c and d). Adenosine may, however, induce
further post-glomerular vasodilation via A2R instead of
preglomerular vasocontraction (in accordance with the
concept that activation of adenosine receptors of type
A1 leads to constriction of afferent arterioles and that
of type A2 to dilation of post-glomerular arteries) [183].
Therefore, the beneficial effect of SGLT2 inhibitors on
the renal hemodynamics of these T2D patients with
RAS blockade is most likely due to enhancement of
post-glomerular vasodilatation in patients with T2D, as
illustrated in Fig. 8b.
Are the effects of SGLT2 inhibitors on renal
hemodynamics in T1D and T2D different?
While the effects in the T1D in young adults revealed reduc-
tion of hyperfiltration and intraglomerular pressure by vaso-
constriction of afferent arterioles, the T2D study in older
adults revealed efferent arteriolar vasodilation as the mediator
of the decrease in GFR and intraglomerular pressure. These
are remarkably different effects of SGLT2 inhibitors in two
different patient groups with diabetes. What could be the rea-
son for these differences? First of all, there are important dif-
ferences between the patient cohorts of the two studies that are
beyond the difference of the T1D and T2D pathogenesis.
These include age, glycemic control, blood pressure, and renal
function. All these parameters could affect difference in
SGLT2 inhibitor effects on renal hemodynamics. Notably,
the number of nephrons declines with age (by about 50% in
healthy individuals between 20 and 70 years of age) while the
single-nephron GFR in the remaining glomeruli varies only
slightly [32]. Therefore, the differences observed in the two
studies may be in part a reflection of variability in nephron
numbers among the patient cohorts. Also, there are great renal
structural heterogeneities due to diabetic nephropathy in older
T2D patients compared with younger T1D patients. In addi-
tion, the T2D study comprised a combination therapy with an
ARB drug.
Clinical benefits in T1D and T2D patients
Taken together, SGLT2 inhibitors protect against major ad-
verse kidney outcomes in individuals with T1D and T2D. In
addition, they prevent kidney failure and reduce morbidity in
patients with T2D. Combined therapies in T2D with other
drugs such as ARBs prove ef fec t ive for added
nephroprotective actions. Combination therapies with
SGLT2 inhibitors were found to be relatively free of compli-
cations, as shown by meta-analyses of data from large clinical
studies [112]. In addition, SGLT2 inhibitors turn out to have
general nephroprotective effects, independent of diabetes.
Overall, beneficial effects include lowering arterial blood
pressure, improving blood sugar levels, reduction in blood
uric acid levels, and slowing down progression of diabetic
nephropathy.
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Renal-cardiac benefits of SGLT2 inhibitors
SGLT2 inhibitors exhibit great benefits also for patients with
heart failure but the precise mechanism underlying this renal-
cardiac benefit are not completely understood. Renal autoreg-
ulation could contribute toward the observed favorable effects
in patients with heart failure with reduced ejection fraction
(HFrEF), with and without diabetes, a topic that is currently
under evaluation in clinical trials [91]. In addition, a variety of
accompanied favorable changes may contribute toward these
benefits: improving the blood glucose level, lowering arterial
blood pressure, decrease in body weight and arterial blood
volume, and reduction in uric acid levels. However, none of
these factors fully explains the renal-cardiac benefits.
Recent ly, direct effects of SGLT2 inhibi tors on
cardiomyocytes have been discussed although it is unclear
what physiological role Na+-coupled glucose transporters play
in these cells. Indeed, a recent report reveals that SGLT1 is
expressed in cardiomyocytes from human tissue biopsies at
both the RNA and protein levels. Interestingly, the study re-
vealed that, while there was no expression of SGLT2, SGLT1
was expressed in normal myocardial tissue and significantly
upregulated in ischemia and hypertrophy [33]. The increase in
SGLT1 expression in ischemic and hypertrophic myocardium
was associated with increased phosphorylation in activating
domains of the intracellular second messengers ERK1/2 and
mTOR, thereby mediating PKC-stimulated plasma membrane
expression of SGLT1, representing a potential pharmacologi-
cal target for cardio-protection. However, SGLT2 inhibitors
are poor ligands for SGLT1. Thus, off-target effects of SGLT2
inhibitors that are not related to membrane transporters in
cardiomyocytes cannot be completely excluded in this study.
Safety of SGLT2 inhibitors and adverse effects
Although there is concern that genital infections are common
adverse effects of these inhibitors, with mycotic infections,
urinary tract infections, and osmotic diuresis, meta-analyses
of trials and a large population-based cohort study indicated
that there is no increased risk, providing reassurance for pa-
tients [199]. Since SGLT2 inhibitors are, however, a fairly
new class of drugs, information on long-term adverse effects
are not available yet. The safety of SGLT2 inhibitors is, how-
ever, warranted due to their highly SGLT2-selective nature.
As indicated above, SGLT2-selective inhibitors do not signif-
icantly inhibit intestinal SGLT1, which is important to prevent
diarrhea that would be caused when SGLT1 would be highly
inhibited, similar to glucose/galactose malabsorption [178]. In
the kidney, SGLT2-selectivity is also important from the safe-
ty point of view. When SGLT2 in the proximal portion of the
renal proximal tubules is completely inhibited, downstream
SGLT1 in the distal portion of the proximal tubule compen-
sates for the glucose reabsorption. When SGLT1 is fully func-
tional, it can reabsorb 120 g of glucose per day, whereas under
euglycemic conditions, it is responsible for the reabsorption of
only 20 g of glucose per day [1]. This compensation of glu-
cose reabsorption by SGLT1 is important to prevent hypogly-
cemia when using SGLT2 inhibitors for the treatment of dia-
betic patients. In fact, the individuals with familial renal
glucosuria, a genetic loss of SGLT2 function, do not generally
suffer from hypoglycemia, an observation which supports the
safety of the use of SGLT2 inhibitors [186]. Therefore, it is
crucial that SGLT2 inhibitors do not inhibit SGLT1 in the
renal proximal tubules. Based on the plasma concentration
and protein binding of the SGLT2 inhibitor canagliflozin, it





Fig. 8 Hypothesized renal
hemodynamic effects of SGLT2
inhibitors: a and b beneficial
effects in type 1 diabetes patients;
c and d beneficial effects in type 2
diabetes patients treated with a
renin-angiotensin system (RAS)
blocker
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tubules where the drug inhibits SGLTs by binding them from
the luminal side [107, 116]. Similarly, SGLT2 inhibitors are
expected not to affect SGLT1 expressed in the heart and skel-
etal muscle when used at clinical doses, which would further
support the safety of the drugs [116].
The highly SGLT2-selective nature has been an important
requirement for SGLT2 inhibitors as described above.
Therefore, SGLT2 inhibitors with high selectivity that are
not affecting other SGLTs have been developed and launched
as therapeutic drugs [6]. However, it has been recognized that
α-glucosidase inhibitors that eventually suppress glucose ab-
sorption from the small intestine are effective in the control of
postprandial hyperglycemia that most anti-diabetic agents are
not able to normalize, even though they reduce fasting blood
glucose levels [8]. Because the inhibition of glucose absorp-
tion from the small intestine would have a beneficial contri-
bution to the anti-diabetic action, the partial inhibition of
SGLT1 in the small intestine without causing diarrhea has
been considered. Among SGLT2 inhibitors currently used
clinically, canagliflozin shows less selectivity to SGLT2
[89]. Furthermore, because canagliflozin shows the highest
plasma protein binding, a higher dose is set for clinical usage
[116]. Therefore, canagliflozin, when administered orally, in-
hibits glucose absorption from the upper small intestine tran-
siently and partially, which does not cause diarrhea but con-
tributes to reduce postprandial hyperglycemia [107, 116, 128].
Furthermore, the transient, partial inhibition of glucose ab-
sorption from the upper small intestine causes a partial shift
of glucose absorption from the upper to lower small intestine
and eventually increases glucose absorption from the lower
small intestine, which increases the secretion of incretin GLP-
1 from the lower small intestine [128]. This also contributes to
anti-diabetic action of canagliflozin, which is the characteristic
feature of canagliflozin among SGLT2 inhibitors.
The effect of SGLT2 inhibitors on bone fractures has re-
cently been discussed. Evidence indicating the direct effect of
SGLT2 inhibitors on fracture risk is lacking and an increased
number of falls probably contributes to fractures [131].
SGLT2 inhibitors might indirectly increase bone turnover by
weight loss. Determining the relevance of the effect of SGLT2
inhibitors on bone fractures and mineral metabolism in T2D,
however, requires further investigation [189].
Future perspectives
While the transport mechanisms and physiological roles of
human SGLT1 in intestine and kidney have been extensively
studied, there are emerging observations for new roles in other
tissues that require further attention. These include expression
in the heart, where its role is completely unknown or in the
brain where it is proposed contribute to glucose sensing. Some
of the SGLT2 inhibitors can also interact with SGLT1 and,
thus, while being beneficial for diabetes treatment, they could
affect some of these other functions as well. Also, while
SGLT2 expression was thought to be largely confined to the
early proximal tubules of the kidney, recent studies reveal
expression in certain cancer types as well. This opens new
opportunities for the development of cancer therapies using
SGLT2 inhibitors, thereby blocking delivery of glucose into
cancer cells and impairing energy production.
More studies are also needed to uncover the physiological
roles of other members of the SLC5 family. Suitable experi-
mental tools are needed to define the true role of SGLT3, a
potentially interesting protein that might act as a glucose sen-
sor. However, further examination of this hypothesis is still
needed. Also, only sparse information is available on SGLT4,
a transporter that is particularly interesting as it seems to reab-
sorb the metabolite 1,5-anhydroglucitol in the kidney. Since
an FDA-approved clinical test for diabetes patients is in use
that might depend on the functional activity of SGLT4, further
studies of the role of this transporter in health and disease
would be valuable. Also, information on SGLT5 is still very
limited. The expression pattern of both SGLT4 and SGLT5 in
intestine and kidney somewhat resembles that of SGLT1 and
SGLT2. However, they do not appear to function as backup
Na+-dependent glucose transporters and they exhibit different
sugar specificities compared with SGLT1 and SGLT2.
Therefore, it will be important to clarify their specific contri-
butions toward solute transport in intestine and kidney.
While the existing bacterial vSGLT and SiaT structures
have contributed significantly to our understanding of the
mechanism of inhibition of gliflozins, their detailed action
on human SGLTs is still unknown. Structural biology efforts
to elucidate the atomic structures of human SGLTs in complex
with substrates and/or inhibitors are warranted. Such struc-
tures could also help to answer the question to what extent
the selectivity of these compounds depends on particular dy-
namic properties of SGLTs or the interaction of the inhibitors
with specific protein side-chains.
Identifying further the precise mechanisms of the effects of
SGLT2 inhibition on renal hemodynamics and how they dif-
fer in T1D and T2D patients, as well as further uncovering the
regulation mechanisms of SGLT2 upregulation in early renal
proximal tubules in the diabetic states and the compensatory
mechanisms of upregulation of SGLT1 in late renal proximal
tubules in the absence of SGLT2, may provide a foundation
for future drug discovery and strategies for novel patient-
tailored therapies, including combination therapies.
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